348 related articles for article (PubMed ID: 30858012)
41. Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis.
Vázquez-Bourgon J; Ortiz-García de la Foz V; Gómez-Revuelta M; Mayoral-van Son J; Juncal-Ruiz M; Garrido-Torres N; Crespo-Facorro B
Int J Neuropsychopharmacol; 2022 Oct; 25(10):795-806. PubMed ID: 35641112
[TBL] [Abstract][Full Text] [Related]
42. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
43. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
44. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
45. Editorial: Making Use of What We Know: Medical Decision-Making and Antipsychotics.
Edelsohn GA
J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1051-1053. PubMed ID: 30928730
[TBL] [Abstract][Full Text] [Related]
46. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
[TBL] [Abstract][Full Text] [Related]
47. Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials.
Kishi T; Ikuta T; Sakuma K; Matsuda Y; Iwata N
J Psychiatr Res; 2019 Aug; 115():121-128. PubMed ID: 31128502
[TBL] [Abstract][Full Text] [Related]
48. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
49. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
Arango C; Giráldez M; Merchán-Naranjo J; Baeza I; Castro-Fornieles J; Alda JA; Martínez-Cantarero C; Moreno C; de Andrés P; Cuerda C; de la Serna E; Correll CU; Fraguas D; Parellada M
J Am Acad Child Adolesc Psychiatry; 2014 Nov; 53(11):1179-90,1190.e1-4. PubMed ID: 25440308
[TBL] [Abstract][Full Text] [Related]
50. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Morlán-Coarasa MJ; Arias-Loste MT; Ortiz-García de la Foz V; Martínez-García O; Alonso-Martín C; Crespo J; Romero-Gómez M; Fábrega E; Crespo-Facorro B
Psychopharmacology (Berl); 2016 Dec; 233(23-24):3947-3952. PubMed ID: 27620899
[TBL] [Abstract][Full Text] [Related]
51. Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
Mustafa S; Joober R; Iyer S; Shah J; Lepage M; Malla A
J Clin Psychiatry; 2019 Aug; 80(5):. PubMed ID: 31509359
[TBL] [Abstract][Full Text] [Related]
52. The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population.
Pan PY; Lee MS; Yeh CB
BMC Psychiatry; 2015 Jan; 15():1. PubMed ID: 25609320
[TBL] [Abstract][Full Text] [Related]
53. Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone).
Shymko G; Grace T; Jolly N; Dobson L; Hacking D; Parmar A; Kapi P; Waters F
Early Interv Psychiatry; 2021 Aug; 15(4):787-793. PubMed ID: 32715655
[TBL] [Abstract][Full Text] [Related]
54. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Ronsley R; Nguyen D; Davidson J; Panagiotopoulos C
Can J Psychiatry; 2015 Oct; 60(10):441-50. PubMed ID: 26720191
[TBL] [Abstract][Full Text] [Related]
55. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
[TBL] [Abstract][Full Text] [Related]
56. Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal.
Hutton P; Taylor PJ; Mulligan L; Tully S; Moncrieff J
Br J Psychiatry; 2015 May; 206(5):360-70. PubMed ID: 25934300
[TBL] [Abstract][Full Text] [Related]
57. Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability.
Noguera A; Ballesta P; Baeza I; Arango C; de la Serna E; González-Pinto A; Parellada M; Graell M; Moreno C; Otero S; Castro-Fornieles J
J Clin Psychopharmacol; 2013 Aug; 33(4):463-71. PubMed ID: 23771198
[TBL] [Abstract][Full Text] [Related]
58. [Atypical antipsychotics in first-episode psychosis: a review].
Rotgé JY; Aouizerate B; Tignol J
Encephale; 2008 Apr; 34(2):194-204. PubMed ID: 18597729
[TBL] [Abstract][Full Text] [Related]
59. A case of extended-release Quetiapine causing recurrent low-grade fevers.
Puthran R; Lai D
Psychiatry Res; 2021 Jan; 295():113583. PubMed ID: 33246590
[TBL] [Abstract][Full Text] [Related]
60. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
